Program
Autologous Tumor Infiltrating Lymphocytes LN-145
Also written as “LN-145”, “Autologous Tumor Infiltrating Lymphocytes” and “LN-145/LN-144”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Sarcoma · Uterine Cervical Neoplasms · Melanoma · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Drug pageAutologous Tumor Infiltrating Lymphocytes LN-145: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Iovance Biotherapeuticsits history only | 61 open or running | phase 2since Mar 14, 2017 | Mar 14, 2017 | Dec 2030phase 2 · NCT04614103 |
| Shanghai Juncell Therapeutics | 22 open or running | phase 2since Apr 24, 2026 | Jun 18, 2024 | Jan 1, 2027phase 1 · NCT06473961 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shanghai Juncell Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 18, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06473961 · 20 planned · China
- Apr 24, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07560111 · 28 planned · China
Ahead
- Jan 1, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06473961
- Jun 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07560111
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Shanghai Juncell Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07560111Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 1, 2027 | 28 |
| NCT06473961Carcinoma, Non-Small-Cell Lung · China | 1 | Recruiting | Jan 1, 2027 | 20 |
How it is read
Names in the registry
- “LN-145”, 6 entries
- “Autologous Tumor Infiltrating Lymphocytes”, 2 entries
- “LN-145/LN-144”, 1 entry
- “LN-145 + pembrolizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Sarcoma, 1 study
- Uterine Cervical Neoplasms, 1 study
- Melanoma, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.